Phenotypic Characteristics and Function of NK Cell Subsets in cART-Treated HIV-1-Infected Individuals

Natural killer (NK) cell plays an important role in an innate immune response against viral infection. The kinetics regulation and functional consequences of NK cells in the pathogeneses of diseases are uncertain. We analyzed NK cell distribution and function of successfully combination antiretroviral therapy (cART)-treated HIV-1 infected individuals in Khon Kaen Regional Hospital, Thailand. The results demonstrated that increased percentage and the total number of NK cell in cART-treated HIV-1 infected patients with preferential high levels of CD56dimCD16+ and CD56-CD16+ subsets when compared with a control group even in undetectable viral load (γ production implied the impairment of cytolytic activity was not recovered after cART treatment. Thus, altered NK cell frequency and function by HIV-1 infection are not completely recovered with cART, which may contribute to impaired cellular immune response and persistence of HIV-1.

[1]  M. Altfeld,et al.  Changes in Natural Killer Cell Activation and Function during Primary HIV-1 Infection , 2013, PloS one.

[2]  S. Nielsen,et al.  Incomplete Immune Recovery in HIV Infection: Mechanisms, Relevance for Clinical Care, and Possible Solutions , 2012, Clinical & developmental immunology.

[3]  H. Ljunggren,et al.  CD56 negative NK cells: origin, function, and role in chronic viral disease. , 2010, Trends in immunology.

[4]  M. Ballmaier,et al.  Phenotypically and functionally distinct subsets contribute to the expansion of CD56−/CD16+ natural killer cells in HIV infection , 2010, AIDS.

[5]  S. Okada,et al.  Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: Reversion by anti-viral treatment. , 2010, Biochemical and biophysical research communications.

[6]  A. Lazzarin,et al.  Perturbation of the natural killer cell compartment during primary human immunodeficiency virus 1 infection primarily involving the CD56bright subset , 2010, Immunology.

[7]  P. Morlat,et al.  Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Altfeld,et al.  NK cells in HIV‐1 infection: evidence for their role in the control of HIV‐1 infection , 2009, Journal of internal medicine.

[9]  S. Pahwa,et al.  IL-21 augments natural killer effector functions in chronically HIV-infected individuals , 2008, AIDS.

[10]  M. Caligiuri,et al.  Human natural killer cells. , 2008, Blood.

[11]  Anne M Johnson,et al.  Changes in the risk of death after HIV seroconversion compared with mortality in the general population. , 2008, JAMA.

[12]  Veronica D. Gonzalez,et al.  Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin. , 2008, Clinical Immunology.

[13]  L. Kallings,et al.  The first postmodern pandemic: 25 years of HIV/ AIDS , 2008, Journal of internal medicine.

[14]  Kallings Lo,et al.  The first postmodern pandemic: 25 years of HIV/ AIDS. , 2008 .

[15]  Chang‐you Wu,et al.  Phenotypically and functionally distinct subsets of natural killer cells in human PBMCs , 2008, Cell biology international.

[16]  E. Rosenberg,et al.  Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. , 2007, The Journal of infectious diseases.

[17]  Richard D Moore,et al.  Risk of Non-AIDS-Related Mortality May Exceed Risk of AIDS-Related Mortality Among Individuals Enrolling Into Care With CD4+ Counts Greater Than 200 Cells/mm3 , 2007, Journal of acquired immune deficiency syndromes.

[18]  D. Follmann,et al.  Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection , 2006, The Journal of experimental medicine.

[19]  Todd M. Allen,et al.  Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. , 2006, The Journal of infectious diseases.

[20]  L. Lanier,et al.  Natural killer cells as an initial defense against pathogens , 2006, Current Opinion in Immunology.

[21]  Hendrik Streeck,et al.  Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. , 2005, Blood.

[22]  A. Fauci,et al.  NK cells in HIV infection: Paradigm for protection or targets for ambush , 2005, Nature Reviews Immunology.

[23]  E. Thiel,et al.  CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets , 2005, Leukemia.

[24]  A. Fauci,et al.  Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Jessica M Malenfant,et al.  CD107a as a functional marker for the identification of natural killer cell activity. , 2004, Journal of immunological methods.

[26]  Jessica M Malenfant,et al.  Increased Natural Killer Cell Activity in Viremic HIV-1 Infection1 , 2004, The Journal of Immunology.

[27]  M. Caligiuri,et al.  The biology of human natural killer-cell subsets. , 2001, Trends in immunology.

[28]  D. Nixon,et al.  Immune reconstitution of CD56(dim) NK cells in individuals with primary HIV-1 infection treated with interleukin-2. , 2008, The Journal of infectious diseases.